Integrin antagonists are effective and safe for Crohn's disease: A meta-analysis

被引：6
作者：
Ge, Wen-Song [1 ]
Fan, Jian-Gao [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai Xinhua Hosp, Dept Gastroenterol, Shanghai 200092, Peoples R China
来源：
WORLD JOURNAL OF GASTROENTEROLOGY | 2015年 / 21卷 / 15期
基金：
中国国家自然科学基金;
关键词：
Crohn's disease; Drug efficacy; Integrin antagonist; Meta-analysis; Drug safety; INFLAMMATORY-BOWEL-DISEASE; MONOCLONAL-ANTIBODY; ALPHA-4; INTEGRIN; NATALIZUMAB; VEDOLIZUMAB; THERAPY; INDUCTION; TRIAL; TREAT; RISK;
D O I：
10.3748/wjg.v21.i15.4744
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
AIM: To evaluate the efficacy and safety of integrin antagonists, including natalizumab and vedolizumab, in Crohn's disease (CD). METHODS: We carried out a literature search in Pubmed, MEDLINE, EMBASE and the Cochrane Library to screen for citations from January 1990 to August 2014. Data analysis was performed using Review Manager version 5.2. RESULTS: A total of 1340 patients from five studies were involved in this meta-analysis. During 6-12 wk treatment, integrin antagonists increased the rate of clinical response and remission with OR = 1.69, 95% CI: 1.37-2.09 and 1.84, 95% CI: 1.44-2.34, respectively. No significant difference was found between integrin antagonists and placebo treatments regarding their adverse reactions (OR = 1.07, 95% CI: 0.83-1.38) and serious adverse reactions (OR = 0.81, 95% CI: 0.57-1.15). CONCLUSION: The results prove the efficacy and safety of integrin antagonists for CD treatment, although the treatment strategies varied.
引用
收藏
页码：4744 / 4749
页数：6
相关论文
共 21 条
[1]   Crohn's disease [J].
Baumgart, Daniel C. ;
Sandborn, William J. .
LANCET, 2012, 380 (9853) :1590-1605
[2]   Review article: loss of response to anti-TNF treatments in Crohn's disease [J].
Ben-Horin, S. ;
Chowers, Y. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (09) :987-995
[3]   Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy [J].
Bloomgren, Gary ;
Richman, Sandra ;
Hotermans, Christophe ;
Subramanyam, Meena ;
Goelz, Susan ;
Natarajan, Amy ;
Lee, Sophia ;
Plavina, Tatiana ;
Scanlon, James V. ;
Sandrock, Alfred ;
Bozic, Carmen .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (20) :1870-1880
[4]   Inhibition of Leukocyte Trafficking in Inflammatory Bowel Disease [J].
Cominelli, Fabio .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (08) :775-776
[5]   Second-Generation Corticosteroids for the Treatment of Crohn's Disease and Ulcerative Colitis: More Effective and Less Side Effects? [J].
De Cassan, Chiara ;
Fiorino, Gionata ;
Danese, Silvio .
DIGESTIVE DISEASES, 2012, 30 (04) :368-375
[6]   Health-Related Quality-of-Life Evaluation of Crohn Disease Patients After Receiving Natalizumab Therapy [J].
Dudley-Brown, Sharon ;
Nag, Arpita ;
Cullinan, Cory ;
Ayers, Mary ;
Hass, Steve ;
Panjabi, Sumeet .
GASTROENTEROLOGY NURSING, 2009, 32 (05) :327-339
[7]   Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin [J].
Feagan, Brian G. ;
Greenberg, Gordon R. ;
Wild, Gary ;
Fedorak, Richard N. ;
Pare, Pierre ;
McDonald, John W. D. ;
Cohen, Albert ;
Bitton, Alain ;
Baker, Jeffrey ;
Dube, Rlean ;
Landau, Steven B. ;
Vandervoort, Margaret K. ;
Parikh, Asit .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2008, 6 (12) :1370-1377
[8]   Natalizumab for active Crohn's disease. [J].
Ghosh, S ;
Goldin, E ;
Gordon, FH ;
Malchow, HA ;
Rask-Madsen, J ;
Rutgeerts, P ;
Vyhnalek, P ;
Zádorová, Z ;
Palmer, T ;
Donoghue, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (01) :24-32
[9]   Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease? [J].
Gilroy, Leah ;
Allen, Patrick B. .
CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2014, 7 :163-172
[10]   A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease [J].
Gordon, FH ;
Lai, CWY ;
Hamilton, MI ;
Allison, MC ;
Srivastava, ED ;
Fouweather, MG ;
Donoghue, S ;
Greenlees, C ;
Subhani, J ;
Amlot, PL ;
Pounder, RE .
GASTROENTEROLOGY, 2001, 121 (02) :268-274
123